CN114569480A - Application of luteolin and pharmaceutically acceptable salt thereof as dopamine receptor agonist in cosmetics - Google Patents
Application of luteolin and pharmaceutically acceptable salt thereof as dopamine receptor agonist in cosmetics Download PDFInfo
- Publication number
- CN114569480A CN114569480A CN202210183644.3A CN202210183644A CN114569480A CN 114569480 A CN114569480 A CN 114569480A CN 202210183644 A CN202210183644 A CN 202210183644A CN 114569480 A CN114569480 A CN 114569480A
- Authority
- CN
- China
- Prior art keywords
- luteolin
- cosmetic
- use according
- cosmetics
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 title claims abstract description 93
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 title claims abstract description 93
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 title claims abstract description 93
- 235000009498 luteolin Nutrition 0.000 title claims abstract description 93
- 239000002537 cosmetic Substances 0.000 title claims abstract description 40
- 150000003839 salts Chemical class 0.000 title claims abstract description 10
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title claims abstract description 8
- 229940098778 Dopamine receptor agonist Drugs 0.000 title abstract description 5
- 230000000694 effects Effects 0.000 claims abstract description 36
- 230000032683 aging Effects 0.000 claims abstract description 12
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 11
- 108060000200 adenylate cyclase Proteins 0.000 claims description 10
- 102000030621 adenylate cyclase Human genes 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 102000015554 Dopamine receptor Human genes 0.000 claims description 7
- 108050004812 Dopamine receptor Proteins 0.000 claims description 7
- 230000003712 anti-aging effect Effects 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- 230000001815 facial effect Effects 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 230000003828 downregulation Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 210000004709 eyebrow Anatomy 0.000 claims description 4
- 210000004209 hair Anatomy 0.000 claims description 4
- 239000002304 perfume Substances 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 239000002453 shampoo Substances 0.000 claims description 4
- 239000002884 skin cream Substances 0.000 claims description 4
- 230000037380 skin damage Effects 0.000 claims description 4
- 239000000686 essence Substances 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 230000003647 oxidation Effects 0.000 abstract description 9
- 238000007254 oxidation reaction Methods 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 description 41
- 102100020756 D(2) dopamine receptor Human genes 0.000 description 17
- 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 13
- 239000003642 reactive oxygen metabolite Substances 0.000 description 12
- 102000019197 Superoxide Dismutase Human genes 0.000 description 11
- 108010012715 Superoxide dismutase Proteins 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 10
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 229940118019 malondialdehyde Drugs 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008809 cell oxidative stress Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940015975 1,2-hexanediol Drugs 0.000 description 2
- 241001237961 Amanita rubescens Species 0.000 description 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- -1 flavonoid compounds Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000036572 transepidermal water loss Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241001519271 Ajuga Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000123846 Buddleja officinalis Species 0.000 description 1
- 101100341170 Caenorhabditis elegans irg-7 gene Proteins 0.000 description 1
- 241000404844 Callicarpa nudiflora Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007934 lip balm Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of luteolin and pharmaceutically acceptable salts thereof as dopamine receptor agonist in cosmetics, and relates to the field of pharmaceutical cosmetics. The luteolin has a structure shown as a formula (I):
the luteolin is mainly used for preparing cosmetics, and the cosmetics have the effects of resisting oxidation, inflammation or aging and the like.
Description
Technical Field
The invention relates to the field of pharmaceutical cosmetics, in particular to application of luteolin and pharmaceutically acceptable salts thereof as dopamine receptor agonists in cosmetics.
Background
Skin inflammation is a defensive response to exogenous or endogenous noxious stimuli, usually involving the release of pro-inflammatory cytokines and chemokines to recruit inflammatory infiltrates following the recognition of surface or internal (uv radiation, allergens, chemical stimuli) interferences by cells. Ultraviolet (UV) radiation enhances the production of ROS (reactive oxygen species) in skin cells, which in turn induces intracellular and extracellular oxidative stress, which not only causes cell damage, but also is susceptible to the development of various diseases.
Dopamine receptors (DRD2) are transmembrane G-protein coupled receptors that, when activated by the endogenous neurotransmitter Dopamine (Dopamine) or agonist drugs, lead to stimulation of inhibitory G-proteins (Gi) and inhibition of adenylate cyclase, thereby causing a series of changes in downstream pathways. DRD2 is located on the cell surface of peripheral nervous system (peripheral nerve endings) and immune system, and includes lymphocytes, NK cells, monocytes, macrophages, fibroblasts, etc. After being activated, the DRD2 can be applied to biological processes such as inflammation, aging, cell proliferation, skin wound healing and the like, so that the development of DRD2 agonist activity for resisting skin inflammation, aging and the like has important research significance.
Disclosure of Invention
The invention aims to provide application of luteolin serving as a dopamine receptor agonist in resisting skin injury caused by ultraviolet rays.
The invention provides application of luteolin and pharmaceutically acceptable salts thereof as dopamine receptor agonists in cosmetics, wherein the luteolin has a structure shown as a formula (I):
further, the cosmetic has at least one of antioxidant, anti-inflammatory or anti-aging effects.
Further, the luteolin acts as at least one of antioxidant, anti-inflammatory or anti-aging effects by ameliorating ultraviolet-induced skin damage.
Further, the luteolin inhibits the expression of at least one of oxidative, inflammatory or aging markers by activating dopamine receptors, inhibiting the activity of adenylate cyclase and promoting the down-regulation of cyclic adenosine monophosphate.
Further, the cosmetic is a facial cleanser, makeup remover, cleansing cream, toilet water, toilet powder, bath lotion, shampoo, skin cream, milky lotion, essence, toilet water, pack, lipstick, lip balm, hair conditioner, foundation, rouge, eye shadow, eyeliner, eyebrow pencil, perfume, foundation, makeup base, or foundation.
Further, the concentration of the luteolin in the cosmetic is 20mg/L-60 mg/L.
Furthermore, the concentration of the luteolin on cells is 4.5mg/L-12 mg/L.
The invention also provides a cosmetic which comprises the luteolin and pharmaceutically acceptable salts thereof.
The invention has the following advantages:
the luteolin provided by the invention can effectively activate dopamine receptors, and has good activity in the aspects of oxidation resistance, inflammation resistance or aging resistance and the like. And luteolin has low cytotoxicity. The change of markers related to intracellular oxidative damage, such as MDA (malondialdehyde), ROS (reactive oxygen species), SOD (superoxide dismutase) and mRNA expression quantity of genes related to inflammation is analyzed and evaluated, so that the luteolin can be used as a dopamine receptor agonist and shows excellent activity in the aspects of oxidation resistance, inflammation resistance or aging resistance and the like.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate an embodiment of the invention and, together with the description, serve to explain the invention and not to limit the invention. In the drawings:
FIG. 1 is a graph of the effect of luteolin on cyclic adenosine monophosphate (cAMP) downstream of dopamine receptors;
FIG. 2 is a cytotoxicity assay for luteolin;
FIG. 3 is a graph of the effect of luteolin on UV-induced lipid oxidation levels in a cell model;
FIG. 4 is a graph showing the effect of luteolin on the superoxide dismutase activity of a UV-induced cell model;
FIGS. 5a and 5b are graphs showing the effect of luteolin on the level of reactive oxygen species in a UV-induced cell model;
FIG. 6 is a graph of the effect of luteolin on inflammatory mRNA expression in a UV-induced cell model;
FIG. 7 is a graph showing the effect of luteolin in a mouse UV model.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. The embodiments and features of the embodiments of the present invention may be combined with each other without conflict.
Luteolin (luteolin) belongs to flavonoid compounds, also called yellow flavin and huangshouling, is a bioactive component derived from plants, mainly derived from plants such as Ajuga alba, callicarpa nudiflora, Buddleja officinalis, wild chrysanthemum flower and the like, and also exists in vegetables such as onion, celery and the like. Luteolin has various pharmacological activities, such as anti-tumor, anti-allergic, anti-fibrosis, anti-oxidation and the like, so that luteolin has important effects on human health.
One embodiment of the invention provides application of luteolin and pharmaceutically acceptable salts thereof as dopamine receptor (DRD2) agonists in cosmetics, wherein the luteolin has a structure shown as a formula (I):
in one embodiment of the invention, the luteolin provides at least one of antioxidant, anti-inflammatory, or anti-aging effects by ameliorating ultraviolet-induced skin damage. Specifically, the luteolin can improve the activity of mouse fibroblast superoxide dismutase under the stimulation of Ultraviolet (UV), prevent lipid peroxidation and reduce the level of reactive oxygen, and achieve the anti-inflammatory effect on the skin. Has great application in preventing or improving skin damage caused by ultraviolet rays.
In one embodiment of the invention, luteolin inhibits the expression of oxidative, inflammatory and aging markers by activating DRD2, inhibiting the activity of Adenylate Cyclase (AC) and promoting the down-regulation of cyclic adenosine monophosphate (cAMP). Specifically, luteolin is effective in activating DRD2, reducing Adenylate Cyclase (AC) activity and promoting cyclic adenosine monophosphate (cAMP) down-regulation, and can molecularly inhibit oxidation, inflammation and aging marker mRNA expression.
In one embodiment of the present invention, the cosmetic has at least one of antioxidant, anti-inflammatory or anti-aging effects. According to the embodiment of the invention, the luteolin enables the obtained cosmetics to have activities of oxidation resistance, inflammation resistance, aging resistance and the like by targeting DRD 2. Luteolin has little adverse side effect on skin, and can be added into cosmetics for relieving skin inflammation.
The term "cosmetic" refers to a product which is applied to any part of the human body surface by spreading, sprinkling, spraying or the like, for the purpose of cleaning, perfuming, changing the appearance, correcting the odor of the body, maintaining the health, and maintaining a good condition.
Cosmetics can be classified into cleansing cosmetics, care cosmetics, and beauty/finishing cosmetics according to their main functions.
The cleansing cosmetic comprises: facial cleanser, makeup remover (milk), cleansing cream (honey), toilet water, toilet powder, bath foam, shampoo (water), etc.
The care cosmetic comprises: skin cream (ointment), lotion, essence, cosmetic water, facial mask, lipstick, lip oil, hair conditioner, etc.
The cosmetic/finishing cosmetic comprises: pressed powder, blusher, eye shadow, eyeliner (liquid), eyebrow pencil, perfume, foundation, makeup, pressed powder, etc.
Preferably, in an embodiment of the present invention, the cosmetic is facial cleanser, makeup remover, cleansing cream, toilet water, toilet powder, bath foam, shampoo, skin cream, lotion, essence, cosmetic water, mask, lipstick, lip oil, hair conditioner, pressed powder, blusher, eye shadow, eyeliner, eyebrow pencil, perfume, foundation, makeup base, pressed powder, etc.
In one embodiment of the invention, the concentration of luteolin in the cosmetic is 20mg/L-60 mg/L. Preferably, the concentration of luteolin in the cosmetic can be 25mg/L, 35mg/L, 45mg/L, 55mg/L, and the like.
In another embodiment of the invention, the concentration of the effect of luteolin on cells is 4.5mg/L-12 mg/L.
In an embodiment of the present invention, the cosmetic may further include components commonly used in the preparation of cosmetics, such as glycerin, butylene glycol, 1, 2-hexanediol, xanthan gum, caprylyl hydroxamic acid, and purified water, according to the type.
The invention also provides a cosmetic which comprises luteolin and pharmaceutically acceptable salts thereof.
The present invention will be described in detail with reference to examples.
The test materials and sources thereof used in the present invention include:
(1) main experimental drugs and reagents
Luteolin, Dopamine (Dopamine, Chengdumanst Biotech limited Co.)
Total SOD activity assay kit (WST-8 method) (Beyotime Biotechnology, Shanghai Bin Yuntian biotechnology Co., Ltd.)
Lipid oxidation (MDA) detection kit (Beyotime Biotechnology, Shanghai Biyuntian biotechnology Co., Ltd.)
H-E dye liquor kit (Solarbio, Beijing Solaibao science and technology Co., Ltd.)
Active oxygen detection kit (Solarbio, Beijing Solebao science and technology Co., Ltd.)
Improved Masson trichrome dyeing kit (Solarbio, Beijing Solebao science and technology Co., Ltd.)
IL-6, IL-1 beta, TNF-alpha antibodies (Affinity)
DRD2 antibody (Santa Cruz Biotechnology, Annuron (Beijing) Biotech Co., Ltd.)
(2) Cell and experimental animal
Mouse fibroblast cell line (3T 3); KeyGen Biotech (Nanjing, China)
5 week old female Kunming mice: is provided by the experimental animal center of the military medical science institute of the people liberation army of China and the experimental animal technology Limited company of Wei Tonglihua Beijing.
Example 1Effect of luteolin on downstream pathways
1. Effect of luteolin on downstream cyclic adenosine monophosphate (cAMP) signalling
The experiment used a mouse cyclic adenosine monophosphate (cAMP) enzyme linked immunosorbent assay kit (Renjeibio, China) to detect changes in the concentration of cAMP-dependent Protein Kinase A (PKA) in 3T3 cells.
The 3T3 cells were seeded in 6-well plates in two sets, the first being the normal set, the second being the over-expressed DRD2, with three replicates per set of three conditions.
The first group is provided with ctrl group, low-concentration luteolin 5.7246mg/L (20 μ M) group and high-concentration luteolin 11.4492mg/L (40 μ M) group. Adding luteolin under corresponding conditions when the cell density is 30%, and collecting sample after 24 hr for detection.
Setting the group and concentration of the second group and the first group, adding DRD2 plasmid to overexpress DRD2 at a cell concentration of 20%, adding luteolin under corresponding conditions after 48 hours, and collecting and detecting samples after 24 hours.
Diluting the cell suspension with PBS, placing in a sterile tube to make the cell concentration reach 106cells/mL, freeze-thaw repeatedly to release intracellular components, and centrifuge to collect supernatant. The procedure was followed in accordance with the kit procedures, and the OD of each well was measured at a wavelength of 450nm after termination of the reaction. It was explored through this experiment that luteolin inhibits the release of adenylate cyclase by activating dopamine receptors (DRD2), thereby causing a series of changes in downstream pathways. And (3) drawing a linear regression curve of the standard substance in an Excel worksheet, and calculating the concentration value of each sample according to a curve equation. The results are shown in FIG. 1.
As can be seen from fig. 1, both the low dose and high dose groups had lower cAMP signal than the crtl group; the cAMP signal was lower in the high dose group than in the low dose group; in the high dose group, the cells overexpressing DRD2 plus luteolin showed lower cAMP signals than the cells with luteolin alone, as well as the low dose group. This indicates that luteolin can activate DRD2 endogenous to the cell, thereby causing the cAMP signal to be reduced; whereas in the over-expressed DRD2 group, the decrease in cAMP signal was more pronounced, suggesting that more DRD2 was activated by luteolin. Thus, luteolin effectively activates DRD2, decreases Adenylate Cyclase (AC) activity and promotes cyclic adenosine monophosphate (cAMP) down-regulation.
Example 2Root of MelilotusDetection of cellular toxicity of grass extract
1. Detection of cell proliferation Activity of luteolin
Cell proliferation capacity was measured by Cell Counting Kit-8(ApexBio, USA). The 3T3 cells were seeded in a 96-well plate (n-3), after overnight incubation, the cells were treated with drugs at different concentrations 2.8623mg/L (10 μ M), 5.7246mg/L (20 μ M), 11.4492mg/L (40 μ M), 22.8984mg/L (80 μ M), 34.3476mg/L (120 μ M), 45.7968mg/L (160 μ M), and 57.246mg/L (200 μ M), and after 24h, the cells were changed, 100ul of the culture medium and 10 μ LCCK-8 solution were added to each well, mixed, and incubated at 37 ℃ for 2h to determine cell viability. With microplate reader (Multiskan)TMFC, Thermo Scientific, USA), the optical density at 450nm was determined. The results are shown in FIG. 2.
As can be seen from FIG. 2, 3T3 was used to test the effect of drugs on cells at different concentrations, and the settings were grouped into control and experimental groups, where the concentrations of drugs in the experimental groups were 2.8623mg/L (10. mu.M), 5.7246mg/L (20. mu.M), 11.4492mg/L (40. mu.M), 22.8984mg/L (80. mu.M), 34.3476mg/L (120. mu.M), 45.7968mg/L (160. mu.M), and 57.246mg/L (200. mu.M), and the optimal concentration of drugs was 20. mu. mol by comparison, indicating that no toxic effect was produced on cells by increasing the drug concentration.
Example 3Research on inhibition of ultraviolet-induced cell damage by luteolin
2.1 Effect of luteolin on UV-induced cell model MDA levels
3T3 was seeded at 50% density in 12-well plates at 37 ℃ with 5% CO2The incubator was used for overnight incubation. A control group, a UV model group and an administration group are set, and the administration group is respectively applied with two concentration gradients of luteolin 5.7246mg/L (20 muM low concentration) and 11.4492mg/L (40 muM high concentration) to pre-protect the cells for 6 h. And (3) performing ultraviolet stimulation on cells of the UV model group and the administration group by using an ultraviolet lamp as a UV source to induce cell oxidative stress, replacing a culture medium for stabilization for 20 minutes after stimulation for 15 minutes, and detecting the intracellular Malondialdehyde (MDA) level by using a lipid oxidation detection kit. The data were statistically analyzed by adding assay reagents according to the manufacturer's protocol and measuring absorbance at 532 nm. The results are shown in FIG. 3.
As can be seen from fig. 3, UV induces oxidative stress in 3T3 cells, significantly increasing the intracellular Malondialdehyde (MDA) content. Luteolin has strong anti-lipid oxidation capability, can effectively reduce the oxidative stress of 3T3 cells induced by UV and lipid peroxidation, and has more obvious performance when the concentration of luteolin is higher.
2.2 Effect of luteolin on UV-induced cell model SOD Activity
3T3 was seeded at 50% density in 12-well plates at 37 ℃ with 5% CO2The incubator was used for overnight culture. A control group, a UV model group and an administration group are set, and the administration group is respectively applied with two concentration gradients of luteolin 5.7246mg/L (20 mu M low concentration) and 11.4492mg/L (40 mu M high concentration) to pre-protect cells for 6 h. Ultraviolet light is used as a UV source, cells of the UV model group and the administration group are subjected to ultraviolet stimulation to induce cell oxidative stress, after 15 minutes of stimulation, the culture medium is replaced and stabilized for 20 minutes, and a total SOD detection kit (Shanghai Biyuntian biotechnology limited) is used for detecting the level of superoxide dismutase in the cells. Assay reagents were added according to the manufacturer's protocol and absorbance values were measured at 450nm and the results were statistically analyzed. The results are shown in FIG. 4.
As shown in FIG. 4, the activity of SOD was strongly protected by luteolin treated cells. Proved that the luteolin can enhance the SOD enzyme activity and improve the damage of the cell SOD activity after UV induction, and the higher the concentration is, the more obvious the protection effect is.
2.3 Effect of luteolin on UV-induced cell model ROS
3T3 was seeded at 50% density in 12-well plates at 37 ℃ with 5% CO2The incubator was used for overnight culture. A control group, a UV model group and an administration group are set, and the administration group is respectively applied with two concentration gradients of luteolin 5.7246mg/L (20 muM low concentration) and 11.4492mg/L (40 muM high concentration) to pre-protect the cells for 6 h. And (3) ultraviolet stimulation is carried out on cells of the UV model group and the administration group by using an ultraviolet lamp as a UV source, cell oxidative stress is induced, after 15 minutes of stimulation, the culture medium is replaced and stabilized for 20 minutes, and the ROS level in the cells is detected by using a reactive oxygen species detection kit. And (3) detecting the fluorescence intensity at 488nm excitation wavelength and 525nm emission wavelength by using a flow cytometer, and calculating the intracellular ROS level. The results are shown inFig. 5a and 5 b.
As can be seen from FIGS. 5a and 5b, UV-induced cells can significantly enhance intracellular reactive oxygen species levels, and cellular reactive oxygen species levels pre-protected by luteolin are significantly reduced, which proves that luteolin has significant advantages in reducing cellular reactive oxygen species levels, and the higher the concentration, the more significant the advantages.
2.4 Effect of luteolin on inflammatory mRNA expression in UV-induced cell models
Total RNA was extracted using MolPure Cell RNA Kit (Yeasen, China) Kit. About 1. mu.g of RNA was reverse transcribed into cDNA using Quantscript RT kit (Tiangen, China). The specific primer transcription was performed using SYBR RT PCR kit (Tiangen, China), and the expression change of the target gene at RNA level was calculated using 2-dd. DELTA. Ct method after Ct value was obtained. The expression level of each gene was normalized to GAPDH expression level. Each data point contains three biological replicates, represented by mean ± SD. The results are shown in FIG. 6.
As can be seen from FIG. 6, UV-induced 3T3 cells promoted the expression of mRNA for inflammatory factors IL-1 β, IL-6, and TNF- α, and the concentration of luteolin was in a positive phase with the inhibitory activity against the expression of UV-induced inflammatory factors, and the effect of 11.4492mg/L (40. mu.M high concentration) luteolin was more pronounced than the effect of 5.7246mg/L (20. mu.M low concentration). The results prove that the luteolin can effectively inhibit the expression of inflammation and aging factors and play the roles of resisting inflammation and aging.
Example 4Luteolin can inhibit ultraviolet induced skin injury of mice
1. Luteolin reduces skin inflammation caused by mouse ultraviolet radiation
Establishing an ultraviolet injury mouse model, and randomly dividing mice into four groups (n is 6): control, UV (Model), UV + luteolin (luteolin was given to the dorsal skin of UV exposed mice every other day at concentrations of 10.01805mg/L (35. mu.M) and 17.1738mg/L (60. mu.M) for 4 weeks, respectively). The amount of UV radiation was 500mJ/cm2Animals were euthanized after 4 weeks of uv exposure and dosing time experiments. The skin tissue on the back of the mice was collected and the pathological structural changes of the skin tissue on the back of the different treatment groups were evaluated by H-E staining. As a result, theSee fig. 7.
As can be seen from fig. 7, the epidermis of the skin of mice was significantly thickened by ultraviolet stimulation, the epidermis was thinned by UV induction with luteolin, and the effect was more significant with the higher the concentration of luteolin, so that luteolin had a better protective effect on the skin by ultraviolet stimulation.
Test example 1Research on anti-inflammatory effect of luteolin-containing emulsion on skin
Two emulsions were prepared by mixing the required substances at the ratios shown in Table 1 below, the concentration of luteolin in the emulsion in Experimental group 1 was 20mg/L, and the concentration of luteolin in the emulsion in Experimental group 2 was 60 mg/L.
TABLE 1
| Additive material | Experimental group 1 (wt%) | Experimental group 2 (wt%) |
| Glycerol | 30％ | 30％ |
| Butanediol | 15％ | 15％ |
| 1, 2-hexanediol | 15％ | 15％ |
| Xanthan gum | 13％ | 13％ |
| Octanoyl |
10％ | 10％ |
| Luteolin | 0.02％ | 0.06％ |
| Purified water | Adding water to 100% | Adding water to 100% |
In order to determine the anti-inflammatory effect of luteolin with different content on human skin, 30 healthy people of 20-40 years old are selected as volunteers and divided into two groups randomly. The left arm of the first group of volunteers is smeared with the emulsion prepared by the experimental group 1, the left arm of the second group of volunteers is smeared with the emulsion prepared by the experimental group 2, and the right arm is smeared with the emulsion which does not contain luteolin and has the same content of other components as the left arm, so that the experimental group and the control group of the experimental group 1 and the experimental group 2 are respectively formed. The test was conducted for a total of 14 days, in which 14 days the arm was exposed to the outside, and the skin condition was measured using a skin measuring instrument on days 0, 4, 7, 10, and 14, respectively, and the results are shown in Table 2. The results were evaluated from the comprehensive scores (average of the volunteers of each group) of four indicators, TEWL (transepidermal water loss), Ultrasound, Elasticity and Skin Color, measured using a dermlab instrument.
TABLE 2
| Experimental group 1 | Control group 1 | |
|
|
| |
66 | 68 | 60 | 58 |
| Day 4 | 68 | 66 | 65 | 59 |
| Day 7 | 71 | 68 | 69 | 58 |
| |
72 | 63 | 72 | 58 |
| Day 14 | 73 | 64 | 78 | 60 |
The test result shows that the emulsion containing the luteolin has good anti-inflammatory and antioxidant effects on the skin, and the anti-inflammatory and antioxidant effects of the luteolin on the skin are in direct proportion to the content of the luteolin.
The present invention is not limited to the above preferred embodiments, and any modifications, equivalent substitutions, improvements, etc. within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (8)
1. Application of luteolin and pharmaceutically acceptable salts thereof as dopamine receptor agonists in cosmetics is characterized in that the luteolin has a structure shown as a formula (I):
2. the use according to claim 1,
the cosmetic has at least one of antioxidant, anti-inflammatory or anti-aging effects.
3. Use according to claim 1,
the luteolin has at least one of antioxidant, anti-inflammatory or anti-aging effects by improving ultraviolet induced skin damage.
4. The use according to claim 1,
the luteolin inhibits the expression of at least one of oxidative, inflammatory or aging markers by activating dopamine receptors, inhibiting the activity of adenylate cyclase and promoting the down-regulation of cyclic adenosine monophosphate.
5. The use according to claim 1,
the cosmetic is facial cleanser, makeup remover, cleansing cream, toilet water, toilet powder, bath lotion, shampoo, skin cream, lotion, essence, cosmetic water, facial mask, lipstick, lip oil, hair conditioner, pressed powder, rouge, eye shadow, eyeliner, eyebrow pencil, perfume, foundation, makeup base, or pressed powder.
6. The use according to claim 1,
the concentration of luteolin in cosmetic is 20mg/L-60 mg/L.
7. The use according to claim 1,
the concentration of the luteolin on the cells is 4.5mg/L-12 mg/L.
8. A cosmetic comprising the luteolin according to any one of claims 1 to 7 and a pharmaceutically acceptable salt thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210183644.3A CN114569480A (en) | 2022-02-25 | 2022-02-25 | Application of luteolin and pharmaceutically acceptable salt thereof as dopamine receptor agonist in cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210183644.3A CN114569480A (en) | 2022-02-25 | 2022-02-25 | Application of luteolin and pharmaceutically acceptable salt thereof as dopamine receptor agonist in cosmetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114569480A true CN114569480A (en) | 2022-06-03 |
Family
ID=81777567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210183644.3A Pending CN114569480A (en) | 2022-02-25 | 2022-02-25 | Application of luteolin and pharmaceutically acceptable salt thereof as dopamine receptor agonist in cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114569480A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107349128A (en) * | 2017-08-21 | 2017-11-17 | 佛山市三水区嘉华化学研究院（普通合伙） | A kind of sorbefacient facial mask |
| CN110420155A (en) * | 2019-09-06 | 2019-11-08 | 苏州榭睿迦医疗科技发展有限公司 | A kind of after-sun recovery antiallergic mask and preparation method thereof for open air after cross-country |
| CN110507645A (en) * | 2019-09-24 | 2019-11-29 | 广东工业大学 | The application of luteolin |
| CN113768917A (en) * | 2021-08-17 | 2021-12-10 | 南方海洋科学与工程广东省实验室(湛江) | Application of luteolin in inhibiting activation of NLRP3 inflammatory corpuscle |
-
2022
- 2022-02-25 CN CN202210183644.3A patent/CN114569480A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107349128A (en) * | 2017-08-21 | 2017-11-17 | 佛山市三水区嘉华化学研究院（普通合伙） | A kind of sorbefacient facial mask |
| CN110420155A (en) * | 2019-09-06 | 2019-11-08 | 苏州榭睿迦医疗科技发展有限公司 | A kind of after-sun recovery antiallergic mask and preparation method thereof for open air after cross-country |
| CN110507645A (en) * | 2019-09-24 | 2019-11-29 | 广东工业大学 | The application of luteolin |
| CN113768917A (en) * | 2021-08-17 | 2021-12-10 | 南方海洋科学与工程广东省实验室(湛江) | Application of luteolin in inhibiting activation of NLRP3 inflammatory corpuscle |
Non-Patent Citations (1)
| Title |
|---|
| 孙洁: "《老年病临床诊疗实践》", pages: 7 - 8 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103479538B (en) | The Dermatologic preparation composition of the flower containing Radix Ginseng or the seed extract of Radix Ginseng | |
| EP2157966B1 (en) | MC-1R, MC-2R, AND/OR µ OPIOID RECEPTORS STIMULATION | |
| US8808761B2 (en) | Composition of skin external application containing rose extract and epigallocatechin gallate(EGCG) | |
| EP3335693B1 (en) | Composition for external use | |
| KR20170133560A (en) | A cosmetic composition for scalp and hair improvement comprising multiple extract of combined medicinal herbs | |
| CN109316478A (en) | The application and drug, cosmetics of a kind of urolithin A in the drug, cosmetics of preparation anti-aging | |
| JPH08176005A (en) | Living body-aging preventive and composition for skin | |
| KR101841118B1 (en) | Composition for skin external application comprising extract of scenedesmus sp. | |
| KR101857282B1 (en) | Cosmetic composition comprising the extract of ishige okamurae | |
| EP2629752B1 (en) | Cosmetic or dermatological composition including an angelica extract, and use thereof for moisturisation and radiance | |
| CN114569480A (en) | Application of luteolin and pharmaceutically acceptable salt thereof as dopamine receptor agonist in cosmetics | |
| CN111135124A (en) | Skin external composition containing mixture of sucrose, indole-3-acetic acid and rose hip extract | |
| JP3998085B2 (en) | Hyaluronic acid amount increase accelerator | |
| CN110840785B (en) | Cosmetic composition for improving skin aging or skin wrinkles | |
| CN114588056A (en) | Theanine-loaded cordycepin compound and preparation method and application thereof | |
| KR20150063485A (en) | Vegfc production promoter | |
| JP2001131045A (en) | Cell-activating agent and cosmetic material containing the same | |
| CN102056585A (en) | Composition for skin external application containing for improving skin wrinkle or skin whitening | |
| KR20090026426A (en) | Composition for moisturizing and improving wrinkle on skin | |
| KR20200137294A (en) | Composition comprising phlorotannin for preventing, improving or treating skin diseases by radiation | |
| CN114404315B (en) | Application of 11-O-mogroside V and pharmaceutically acceptable salt thereof as CB2 receptor agonist in cosmetics | |
| KR102543076B1 (en) | Composition comprising DNA components for suppressing specific gene expression, controlling epigenetic mutation, and improving skin condition | |
| JP6002510B2 (en) | Estrogen receptor β activator | |
| KR20120056225A (en) | Composition for external application comprising fine bubble | |
| JP2018008905A (en) | Anti-skin aging agent and external cosmetics containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220603 |